Pipeline

Ryvu Therapeutics is advancing a broad pipeline by addressing emerging targets in oncology.

Our pipeline includes candidates with differentiated therapeutic mechanisms, including programs directed at kinase, synthetic lethality, and immuno-oncology pathways.

Clinical Projects

  • Program/ Target Name
  • Indication
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Partner
  • Anticipated
    Milestones
  • RVU120
    CDK8/19
    • R/R AML (RIVER-81) (combination therapy)

    • Initial Phase II data in Q4 2024​

    • R/R AML/HR-MDS (RIVER-52) (monotheraphy)

    • Complete Ph I data in 2Q24
      Initial Ph II data in 4Q24      ​

    • Other Hematology ​ (LR-MDS, MF)

    • Initiation of Phase II in mid-2024

    • Solid Tumors

    • Complete Ph I data & Translational Studies in 2024​

  • MEN1703(SEL24
    PIM/FLT3
    • DLBCL

    • Initiation of Ph II in mid-2024​

Discovery & Preclinical Projects

  • Program/ Target Name
  • Indication
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Partner
  • Anticipated
    Milestones

Synthetic Lethality

  • PRMT5
    • Solid tumors

    • IND filing in H2 2025

  • WRN
    • Solid tumors

    • Led to Development
      Candidate in 2024/5

  • NOVEL TARGETS
    • ONCOLOGY

Immuno-oncology

  • STING & MULTI-TARGET IMMUNE MODULATION COLLABORATION
    • ONCOLOGY
  • STING ADC
    • ONCOLOGY